Cód QR

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia Zappasodi
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: MDPI AG 2023-06-01
Sraith:Pharmaceutics
Ábhair:
acute myeloid leukemia
elderly patients
venetoclax
posaconazole
HPLC-MS/MS
dose adjustment
Rochtain ar líne:https://www.mdpi.com/1999-4923/15/6/1680
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla